Comparative Pharmacology
Head-to-head clinical analysis: QALSODY versus VILTEPSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QALSODY versus VILTEPSO.
QALSODY vs VILTEPSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QALSODY (tofersen) is an antisense oligonucleotide that mediates degradation of SOD1 mRNA through RNase H activity, reducing SOD1 protein production.
Antisense oligonucleotide that binds to exon 51 of dystrophin pre-mRNA, excluding it during splicing to restore the reading frame and produce a truncated but functional dystrophin protein in patients with Duchenne muscular dystrophy (DMD) with confirmed mutations amenable to exon 51 skipping.
100 mg intrathecally once every 4 weeks. Administer as a loading dose of 100 mg on days 0, 14, and 28, then every 4 weeks thereafter.
30 mg/kg intravenously once weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 28 days (range 22-35 days) following intrathecal administration; this prolonged half-life supports monthly dosing schedules and reflects slow clearance from the central nervous system.
The terminal elimination half-life is approximately 3-4 weeks in plasma, reflecting slow clearance due to tissue binding and prolonged intracellular retention. Clinically, this supports weekly intravenous dosing.
Primarily excreted unchanged in urine via glomerular filtration and tubular secretion, accounting for approximately 60-70% of the administered dose; biliary/fecal excretion accounts for the remainder (30-40%) as inactive metabolites and parent drug.
Viltepso is primarily eliminated via renal excretion. Approximately 60-70% of the administered dose is excreted unchanged in urine within 24 hours, with minimal biliary/fecal elimination (less than 5%).
Category C
Category C
Antisense Oligonucleotide
Antisense Oligonucleotide